Profile data is unavailable for this security.
About the company
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
- Revenue in USD (TTM)8.23bn
- Net income in USD683.12m
- Incorporated1989
- Employees41.10k
- LocationICON PLCSouth County Business ParkLEOPARDSTOWN, Dublin 18DUBLIN 00000IrelandIRL
- Phone+353 12912000
- Fax+353 12912700
- Websitehttps://www.iconplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris Inc | 15.43bn | 54.70m | 13.74bn | 38.00k | 273.33 | 0.6788 | 4.92 | 0.8907 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.83bn | 1.40k | 56.57 | 6.08 | 51.05 | 7.33 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 15.33bn | 3.40k | 76.44 | 3.02 | 49.34 | 6.20 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
| Alnylam Pharmaceuticals, Inc. | 1.83bn | -440.24m | 18.13bn | 2.10k | -- | -- | -- | 9.92 | -3.59 | -3.59 | 14.46 | -1.75 | 0.4957 | 2.85 | 8.43 | 870,615.30 | -11.94 | -26.56 | -15.61 | -32.77 | 83.02 | 83.66 | -24.08 | -94.26 | 2.99 | -2.11 | 1.28 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| ICON PLC | 8.23bn | 683.12m | 24.63bn | 41.10k | 36.15 | 2.61 | 19.35 | 2.99 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| DuPont de Nemours Inc | 12.07bn | 494.00m | 30.31bn | 24.00k | 69.91 | 1.28 | 18.04 | 2.51 | 1.04 | 0.9256 | 26.77 | 56.45 | 0.302 | 3.50 | 4.94 | 502,833.30 | 1.33 | 0.3709 | 1.48 | 0.468 | 35.08 | 35.69 | 4.42 | 1.97 | 1.73 | 6.61 | 0.2398 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Biogen Inc | 9.66bn | 1.17bn | 31.28bn | 7.57k | 26.84 | 2.06 | 18.43 | 3.24 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Gartner Inc | 5.97bn | 797.23m | 32.12bn | 20.29k | 41.06 | 44.93 | 32.41 | 5.38 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| Holder | Shares | % Held |
|---|---|---|
| WCM Investment Management LLCas of 31 Mar 2024 | 6.72m | 8.14% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 5.53m | 6.71% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 3.43m | 4.16% |
| Lazard Asset Management LLCas of 31 Dec 2023 | 2.76m | 3.35% |
| Boston Partners Global Investors, Inc.as of 31 Dec 2023 | 2.67m | 3.24% |
| Ninety One UK Ltd.as of 31 Mar 2024 | 2.65m | 3.21% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.59m | 3.14% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 2.55m | 3.10% |
| Comgest SAas of 31 Dec 2023 | 1.54m | 1.87% |
| AllianceBernstein LPas of 31 Dec 2023 | 1.54m | 1.86% |
